The short version
22 companies list this market — deep enough that no single failure threatens the supply. The generic price has fallen 30% in a year, to $4.19 per unit. The brand runs $7.49 per unit — 1.8× more.
ⓘ How this was built
- FDA NDC Directory (openFDA) — labelers active in the last 30 days, repackagers classified from DailyMed SPL establishment roles
- CMS NADAC — latest price vs the price in effect ~12 months earlier
- FDA drug shortages and enforcement reports (openFDA)
- FDA inspection classifications; DrugDashboards fragility score and 90-day shortage model
Each sentence is a template that fires only when its condition holds in the data shown lower on this page: maker counts are distinct FDA labelers listing this molecule and dosage form in the last 30 days minus classified repackagers; the price trend compares the newest NADAC with the last price in effect at least 9 months earlier; shortage and recall sentences restate FDA rows for this drug's presentations (Class I/II, trailing 12 months); the plant sentence needs a MANUFACTURE-role establishment with a drug-quality OAI in 24 months; the verdict restates the fragility band; the risk sentence appears only when the model's probability is at least 1.5× the typical market. Nothing here is inferred beyond those rules.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.